Nov 5, 2024, New York, NY — Cayuga Biotech, a company that develops drugs that harness the body’s innate ability to stop bleeding, will be presenting severe animal injury model data for its first generation, first-in-class, polyphosphate (polyP)-based therapy at the 66th American Society of Hematology (ASH) Annual Meeting and Exposition in San Diego, California from December 7-10, 2024.
ASH Presentation Details:
Title: A Novel Synthetic Short-Chain Polyphosphate (polyP) Complexed with Silica Nanoparticle (SNP) Improves Hemostatic Outcomes in Severe Swine and Rat Injury Models
Publication Number: 3964
Session Name: 321. Coagulation and Fibrinolysis: Basic and Translational: Poster III Session Date: Monday, December 9, 2024
Presentation Time: 6:00 PM – 8:00 PM
Location: San Diego Convention Center, Halls G-H
About Hemorrhage
Nearly 2 million people globally per year die of hemorrhage, the majority of which is preventable. The top causes of preventable death by hemorrhage are non-compressible hemorrhage sites (such as internal bleeding and penetrating injury) and delays in hemostatic control neither of which are adequately addressed by today’s current care model. Due to the nature of non-compressible hemorrhage sites, the complexity of clinical intervention is time consuming and delays in treatment often lead to patient death.
About Cayuga Biotech, Inc.
Cayuga is developing novel biomimetic therapies leveraging inorganic polyphosphate, a polymer that modulates the healing response. The company has an optimized polyP-SNP complex in late preclinical development for the treatment of acute major hemorrhage, a discovery-stage novel composition for the treatment of inherited bleeding disorders, as well as a portfolio of early-stage programs focused across the healing continuum. To learn more, please visit www.CayugaBiotech.com.
Contact:
Andrea Ashford-Hicks
Media@cayugabiotech.com